News | June 06, 2022
Merck’s pembrolizumab demonstrates improvement in distant metastasis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
Supply increase to help meet growing global demand
No new studies have been requested
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Subscribe To Our Newsletter & Stay Updated
